作者：
Maheshi N,Ramasamy [1]
;
Elizabeth J,Kelly [2]
;
Seth,Seegobin [3]
;
Paul I,Dargan [4]
;
Ruth,Payne [5]
;
Vincenzo,Libri [6]
;
Matthew,Adam [7]
;
Parvinder K,Aley [8]
;
Nuria,Martinez-Alier [9]
;
Alison,Church [10]
;
Brett,Jepson [11]
;
Mark,Khan [12]
;
Sam,Matthews [3]
;
G Todd,Townsend [13]
;
Johan,Vekemans [14]
;
Sagida,Bibi [8]
;
Phillip A,Swanson [2]
;
Teresa,Lambe [15]
;
Menelas N,Pangalos [16]
;
Tonya,Villafana [17]
;
Andrew J,Pollard [8]
;
Justin A,Green [18]
;
AZD2816 Study Group
作者单位：
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; National Institute for Health and Care Research, Oxford Biomedical Research Centre, Oxford, UK.
[1]
Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
[2]
Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
[3]
Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK; Faculty of Life Sciences and Medicine, King's College London, London, UK.
[4]
Department of Infection, Immunity and Cardiovascular Disease, The Medical School, University of Sheffield, Sheffield, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
[5]
National Institute for Health and Care Research, University College London Hospitals, Clinical Research Facility, London, UK; National Institute for Health and Care Research, University College London Hospitals, Biomedical Research Centre, London, UK.
[6]
Clinical Infection Research Group-Edinburgh, Regional Infectious Diseases Unit, NHS Lothian, Edinburgh, UK.
[7]
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; National Institute for Health and Care Research, Oxford Biomedical Research Centre, Oxford, UK.
[8]
Formerly Paediatric Infectious Diseases and Immunology, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK; IQVIA, London, UK.
[9]
Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA.
[10]
Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
[11]
Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Mississauga, ON, Canada.
[12]
Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
[13]
Formerly Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
[14]
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK; Chinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, UK.
[15]
BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
[16]
Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
[17]
Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: justin.green@astrazeneca.com.
[18]
DOI
10.1016/S2666-5247(23)00177-5
PMID
37783221
发布时间
2024-03-26
换一批
换一批
